74676-47-4

Upstream product

• 98-59-9 p-toluenesulfonyl chloride 
• 10563-26-5 N,N'-bis(3-aminopropyl)-1,2-diamine 
• 7732-18-5 water 
• 36394-60-2 3,8-dioxo-4,7-diazadecanediamide 
• 477808-21-2 N-[2-(2-methoxycarbonyl-acetylamino)-ethyl]-malonamic acid methyl ester 

Downstream Products

• 120808-61-9 4,8,11,15-tetrakis(p-tolylsulphonyl)-1-oxa-4,8,11,15-tetraazacycloheptadecane 
• 129886-67-5 1,4,7,10,14,17-Hexakis-(toluene-4-sulfonyl)-1,4,7,10,14,17-hexaaza-cycloicosane 
• 120808-62-0 7,11,14,18-tetrakis(p-tolylsulphonyl)-1,4-dioxa-7,11,14,18-tetra-azacycloicosane 
• 71089-74-2 1,4,8,11-tetrakis(p-toluenesulphonyl)-1,4,8,11-tetraazacyclotetradecane 
• 180678-12-0 4,8,11,15-Tetrakis(p-tolylsulfonyl)-4,8,11,15-tetraazaoctadecane-1,18-diamine 
• 15439-16-4 1,4,8,12-Tetraazacyclopentadecan 
• 295-37-4 1,4,8,11-Tetraazacyclotetradecane 
• 334528-87-9 N,N',N'',N'''-tetratosyl-2,6,9,13-tetraaza[14]metacyclophane 
• 69038-12-6 1,4,8,12-tetrakis(p-tolylsulphonyl)-1,4,8,12-tetra-azacyclopentadecane 
• 77320-31-1 1,4,7,11,14-pentatosyl-1,4,7,11,14-pentaazacycloheptadecane 
• 150059-50-0 16,17,19,20-Tetramethyl-N,N',N'',N'''-tetratosyl-2,6,9,13-tetraaza<14>paracyclophane 
• 120808-63-1 10,14,17,21-tetrakis(p-tolylsulphonyl)-1,4,7-trioxa-10,14,17,21-tetra-azacyclotricosane 
• 148873-87-4 N,N',N'',N'''-tetrakistosyl-2,6,9,13-tetraaza<14>paracyclophane 
• 74676-48-5 1,5,8,12-N,N',N'',N'''-terakis(p-toluenesulfonyl)tetraazacyclohexadecane 

Relevant academic research and scientific papers

ARENE CONNECTED POLYAMINE MACRORING DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF

Abstract: The present invention relates to arene connected polyamine macrocyclic derivatives represented by general formula I, pharmaceutically acceptable salts or hydrates thereof which have anti-HIV activities, in which the definitions of substituents are as defined in the description; to preparation methods of the compounds of formula I; to pharmaceutical compositions containing the compounds of formula I or their pharmaceutically acceptable salts or hydrates; to the use of the compounds of formula I or their pharmaceutically acceptable salts or hydrates for the preparation of a medicament for the treatment and prevention of HIV-associated diseases.

Polyaza metacyclophanes as ditopic anion receptors

Five macrocyclic polyaza metacyclophanes L1-L5 prepared by dipode coupling of the tosylated precursors have been studied. The basicity of the ligands has been measured potentiometrically and their ability to complex halides and perch

Chemoenzymatic syntheses of polyamines and tetraazamacrocycles

Syntheses of different open chain polyamines starting from enzymatically prepared bis(amidoesters) are described. Some of these polyamines are also used as precursors in the syntheses of tetraazamacrocycles. This methodology can also be applied to the synthesis of chiral compounds.

Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide

The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: STR1 wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

Methods of preparing manganese complexes of nitrogen-containing macrocyclic ligands

The present invention is directed to low molecular weight mimics of superoxide dismutase (SOD) represented by the formula: STR1 wherein R, R', R1, R'1, R2, R'2, R3, R'3, R4, R'4, R5, R'5, R6, R'6, R7, R'7, R8, R'8, R9, and R'9 and X, Y, Z and n are as defined herein, useful as therapeutic agents for inflammatory disease states and disorders, ischemic/reperfusion injury, stroke, atherosclerosis, hypertension and all other conditions of oxidant-induced tissue damage or injury.

Polyazacyclophanes. 2,6,9,13-Tetraazaparacyclophane as a Cationic and Anionic Receptor

The synthesis and characterization of the new azacyclophane, 2,6,9,13-tetraazaparacyclophane, is described.The acid-base behaviour and the metal and anion coordination capabilities of this compound have been studied by potentiometry at 298.15 K in 0.1

MACROHETEROCYCES. XXXVI. A CONVENIENT METHOD FOR SYNTHESIS OF DI- AND POLYAZACROWN ETHERS

A method is proposed for the production of di- and polyazacrown ethers by the condensation of bissulfonamides with dibromides or ditosyloxy derivatives in a two-phase aqueous alkali-toluene (benzene) system.The optimum concentration range for the substrate and the alkylating agent is 0.017-0.1 M.The catalytic activity of the quaternary ammonium salts decreases in the order (Bu)4NI > (Bu4)NBr > (Bu4)NCl > (Bu4)NHSO4 > (C2H5)3C6H5CH2NCl >> (Et)4NI > (Et)4NBr.The highest yields of te 12-membered azacrown ethers are obtained in the presence of lithium hyroxide, and the largest yields of the crown ethers with larger ring sizes are obtained in the presence of sodium or potassium hydroxide, and this is probably due to the matrix effects of the cation.